Business
Change of Registered Office Address
Change of Registered Office Address.
About this update from Immupharma Plc
[{"type":"text","content":"\n \n \n RNS Number : 9805O\n Immupharma PLC\n 05 June 2020\n \n \n \n \n RNS: FOR IMMEDIATE RELEASE 5 June 2020\n \n \n \n \n \n ImmuPharma PLC\n \n \n (\"ImmuPharma\" or the \"Company\")\n \n \n \n \n \n Notification of Change of Registered Office Address\n \n \n \n \n \n ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that with immediate effect, its registered office address has been changed to: \n One Bartholomew Close, London, EC1A 7BL.\n \n \n \n \n \n This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (\"MAR\n \").\n \n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n \n \n \n ImmuPharma PLC (\n \n \n www.immupharma.com\n \n \n )\n \n \n \n Tim McCarthy, Chairman\n \n \n \n \n + 44 (0) 207 152 4080\n \n \n \n \n \n \n Dimitri Dimitriou, Chief Executive Officer\n \n \n \n \n \n \n \n \n \n Lisa Baderoon, Head of Investor Relations\n \n \n \n \n + 44 (0) 7721 413496\n \n \n \n \n \n \n \n \n \n \n \n \n SPARK Advisory Partners Limited (NOMAD)\n \n \n Neil Baldwin\n \n \n \n \n \n \n Stanford Capital Partners (Joint Broker)\n \n \n \n \n Patrick Claridge, John Howes\n \n \n \n \n \n SI Capital (Joint Broker)\n \n \n Nick Emerson\n \n \n \n \n \n \n \n +44 (0)\n 20\n 3 36\n 8 3550\n \n \n \n \n \n \n \n \n +44 (0) 203 815 8880\n \n \n \n \n \n \n \n \n +44 (0) 1483 413500\n \n \n \n \n \n \n \n \n \n \n \n \n 4Reliance (Euronext Growth Listing Sponsor)\n \n \n Jean-Charles Snoy\n \n \n \n \n \n Degroof Petercam (Liquidity Provider)\n \n \n Erik De Clippel\n \n \n \n \n \n Backstage Communication\n \n \n Olivier Duquaine\n \n \n Gunther De Backer\n \n \n \n \n +32 (0) 2 747 02 60\n \n \n \n \n \n \n \n \n +32 (0) 2 287 95 34\n \n \n \n \n \n \n \n \n \n \n \n +32 (0) 477 504 784\n \n \n +32 (0) 475 903 909\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Notes to Editors \n \n \n About ImmuPharma PLC\n \n \n ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeut...